Porton Pharma Solutions & Codexis Launch Global Partnership

Codexis, Inc and Porton Pharma Solutions, Ltd. recently announced a strategic collaboration to deploy Codexis’ world-leading biocatalyst technology within Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business. The partnership will accelerate the creation and commercialization of new, low-cost, sustainable manufacturing processes, exploiting the benefits of biocatalysts to a growing number of the world’s small molecule pharmaceuticals.

Under the terms of the collaboration, Codexis will license core elements of its biocatalyst technologies to Porton, including its proprietary biocatalyst libraries, high-throughput screening, and enzyme manufacturing know-how. Codexis will also provide preferential access to its CodeEvolver protein engineering platform technology for the creation of new biocatalytic process solutions. Porton will install new operations to drive adoption and optimal application of these biocatalyst technologies into its custom contract development and manufacturing (CDMO) offerings to global pharmaceutical customers. Additionally, Porton pledges financial commitments to utilize Codexis’ CodeEvolver protein engineering platform technology.

The partnership reinforces the benefits of reduced costs, enhanced sustainability, and improved product quality that biocatalysts can deliver to the manufacturing of the world’s small molecule pharmaceuticals. These benefits are already impacting a growing set of the world’s drug manufacturing processes and have earned Codexis three US EPA Presidential Green Chemistry Challenge awards for its biocatalysts’ contributions in these commercial-scale drug manufacturing innovations.

“Technological leadership is central to our strategy to grow and deliver value to our pharmaceutical clients around the globe,” said Oliver Ju, Chairman and CEO at Porton Pharma Solutions. “We believe that biocatalysis is the most impactful technology to improve the future of pharmaceutical manufacturing, and there is not a more capable player to partner with than Codexis.”

“We are delighted to establish this unique partnership with Porton,” said John Nicols, President and CEO of Codexis. “Given Porton’s significant and fast-growing presence as a leading global CDMO, we will now be able to reach a greater share of the world’s pharmaceutical manufacturing market.”

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective, and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, visit www.codexis.com.

Porton Pharma Solutions is an industry-leading partner and provider of custom API development and manufacturing services to the global drug industry. Backed by more than 1,700 customer-centric employees, cutting-edge Process R&D Centers, USFDA and PMDA-inspected cGMP production sites and marketing offices located across Asia, North America, and Europe, Porton helps its customers more efficiently deliver improved health outcomes to their patients through chemical process innovation, rapid scale-up and high-quality, cost-effective manufacture of APIs and/or drug intermediates. For more information, visit www.porton.cn.